Breakthrough Australian research mapping how insulin works at a molecular level could open the door to novel new diabetes treatments, ending daily needle jabs for millions, scientists have announced.

A medical assistant administers an insulin shot to a diabetes patient at a private clinic in New Delhi, on November 8, 2011. Breakthrough Australian research mapping how insulin works at a molecular level could open the door to novel new diabetes treatments, ending daily needle jabs for millions, scientists have announced.

A Melbourne team have been able to lay out for the first time how the insulin hormone binds to the surface of cells, triggering the passage of glucose from the bloodstream to be stored as energy.

Lead researcher Mike Lawrence on Thursday said the discovery, more than 20 years in the making, would make new and more effective kinds of diabetes medication possible.

"Until now we have not been able to see how these molecules interact with cells," said Lawrence, from the Walter and Eliza Hall Institute of Medical Research.

"We can now exploit this knowledge to design new insulin medications with improved properties, which is very exciting."

Lawrence said the team's study, published in the latest edition of Nature, had revealed a "molecular handshake" between the insulin and its receptor on the surface of cells.

"Both insulin and its receptor undergo rearrangement as they interact -- a piece of insulin folds out and key pieces within the receptor move to engage the insulin hormone," he said of the "unusual" binding method.

Understanding how insulin attaches to cells was key to developing "novel" treatments of diabetes, a chronic condition in which the pancreas does not produce enough insulin or the body cannot use it properly.

"The generation of new types of insulin have been limited by our inability to see how insulin docks into its receptor in the body," said Lawrence.

"This discovery could conceivably lead to new types of insulin that could be given in ways other than injection, or an insulin that has improved properties or longer activity so that it doesn't need to be taken as often."

Importantly, he said it could also have ramifications for the treatment of diabetes in developing nations, allowing for the creation of more stable insulins that do not need refrigeration.

There are an estimated 347 million diabetes sufferers worldwide and diagnoses are increasing, particularly in developing countries, due to growing levels of obesity and physical inactivity.

It is expected to be the seventh leading cause of death in the world by 2030, with the World Health Organisation projecting total deaths from diabetes will rise by more than 50 percent in the next 10 years.

Complications of diabetes include blindness, limb amputation and kidney failure.

Source: AFP